YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

News Blast

May 12, 2006

Isis Pharmaceuticals granted an exclusive worldwide license to ImQuest Pharmaceuticals for the development and commercialization of ISIS 5320, a potent and specific HIV inhibitor. ImQuest will develop ISIS 5320 as a topical microbicide therapy to prevent sexual transmission of HIV throughout the world, but especially in developing countries.

Oxford Genome Sciences (OGeS) will collaborate with the Department of Clinical Pharmacology at the University of Oxford to discover clinical biomarkers for colorectal cancer. Over the next two years, OGeS will apply its proteomics expertise and proprietary OGAP database to identify new approaches for the early differential diagnosis of early-stage versus late-invasive-stage patients and to identify additional protein biomarkers of recurring disease.

Myriad Genetics and Abbott Laboratories signed a five-year research agreement to identify novel therapeutic targets for a variety of diseases.  Myriad will evaluate differences in DNA and the RNA expression between thousands of individuals to identify the genetic basis of disease. Abbott will advance these genes through its chemical genomics platform to identify targets and leads for drug discovery.

Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.